Clin Gastro H: The sensitivity of fecal immunochemical testing to colorectal cancer depends on the stage and location of the patient's illness

Background and target fecal immunochemical testing (FIT) is widely used for colorectal cancer (CRC) screening.
that although early detection of CRC has a significant effect on reducing CRC mortality, there is limited evidence of FIT sensitivity at specific stages of CRC testing.
, the study speculates that the sensitivity of quantitative FIT in a large number of CRC patients may vary from the stage and location of the patient's illness.
method researchers collected stool samples from 435 newly diagnosed CRC patients.
the sensitivity of quantitative FIT to CRC patients with different T-phases and tumors in the overall TNM phase was calculated in the detection threshold (17 μg/g feces).
results FITT test was 52% sensitive to T1 tumors (95% CI, 37%-67%), and 79% sensitive to T2 tumors (95% CI, 68%-88%), Sensitivity to T3 was 93% (95% CI, 89%-95%) and sensitivity to T4 tumors was 84% (95% CI, 72%-92%) (P trend <.0001 p> Conclusion Although FIT identified CRC patients as a whole with high sensitivity, it may miss about one-third of ICRC.
, the authors conclude that the sensitivity of FIT testing is also related to the stageing of a patient's cancer.